Profile

Cover photo
Advaxis, Inc.
26 followers|12,887 views
AboutPostsPhotosYouTube

Stream

 
Today is the last day of online voting for the ViE (Vaccine Industry Excellence) Awards. Advaxis has been honored to have earned a spot on the shortlist! http://bit.ly/1HPmpEa
The nominations have been counted and we are delighted to announce that the shortlist for the 8th Annual ViE Awards has now been chosen. Join us at the World Vaccine Congress on April 7-9 to…
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced that the first patient was dosed in a Phase 1/2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV for the treatment of patients with recurrent cervical cancer. "Recurrent cervical cancer is a fatal disease that has been resistant to most treatments, with a one-year survival rate of approximately 10-15%. Survival data from the Phase 2 studies with a single cycle of ADXS-HPV at a lower dose in this patient population was encouraging, and we hope that we can improve clinical outcomes by using a higher dose and repeat cycles of treatment," said principal investigator, Dr. Ghamande. http://bit.ly/1FJ0gZh
PRINCETON, N.J., March 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in a Phase 1/2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV (ADXS11-001), ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced that three abstracts revealing new data for the Company's proprietary Lm-LLO cancer immunotherapy platform have been selected for poster presentations at the 2015 American Association for Cancer Research (AACR) Annual Meeting, April 18 – 22, 2015, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. http://bit.ly/1FEaOZF
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies. Additional Late Breaking Abstract to Demonstrate Delay of Tumor Progression and Prolonged Overall Survival in Study of ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis presented preliminary data from the Phase 1/2 clinical study of ADXS-HPV in HPV-associated anal cancer in combination with chemoradiation showing complete response and with no evidence of recurrence to date in all treated patients. In addition, the preliminary data showed the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea. Find out more: http://bit.ly/1Fq5c5f
Data Highlighted in Oral Presentation at the International Anal Neoplasia Society Scientific Meeting 2015. PRINCETON, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
President and CEO, Dan O'Connor, will present at the 27th Annual ROTH Conference on Monday, March 9, 2015 at 5 p.m. PST in Laguna Niguel, CA. http://bit.ly/1EpKLVr
PRINCETON, N.J., March 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the 27th Annual ROTH Conference ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced that an abstract related to ADXS-HPV, the Company's lead Lm-LLO immunotherapy product candidate, has been selected for oral presentation at the International Anal Neoplasia Society (IANS) Scientific Meeting 2015, March 13-15, in Atlanta, Georgia. In addition, Dr. Samir Khleif was selected as the meeting's keynote speaker. http://bit.ly/1LKBQ1D
Phase 1/2 Clinical Study Data on ADXS-HPV in HPV-Associated Anal Cancer Selected for Oral Presentation. Keynote Speech to be Delivered by Samir N. Khleif, M.D., Member of Advaxis's Board of Directors, on Immune-Based Approaches to HPV-Related Cancers. PRINCETON, N.J., Feb.
1
Add a comment...
Have them in circles
26 people
yolande lorijn's profile photo
Christina Kindborg's profile photo
David Miller's profile photo
Katherine Johnston's profile photo
Liz Peters's profile photo
Vincent Grillo's profile photo
jim dooley's profile photo
Eduardo Zawadzki's profile photo
Corsilo Japon's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will present at the 2015 Jefferies Immuno-Oncology Summit on April 15, 2015 in Boston, Massachusetts. CEO Dan O'Connor will discuss the Company's proprietary Lm-LLO cancer immunotherapy platform, clinical programs and business strategy at 12:40 p.m. ET. http://bit.ly/1HMSQmK
PRINCETON, N.J., March 26, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the 2015 Jefferies Immuno-Oncology Summit being held April 15, 2015 at the Boston Harbor Hotel in ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will host an AACR Research Reception at the Ritz Carlton, Philadelphia on April 21, 2015 at 6:30 p.m. http://bit.ly/1FEcUJ6
Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies. Additional Late Breaking Abstract to Demonstrate Delay of Tumor Progression and Prolonged Overall Survival in Study of ...
1
Add a comment...
 
Vaccine Nation recently announced its ViE (Vaccine Industry Excellence) Awards shortlist and we are very excited to be recognized! http://bit.ly/1GXqE09
The nominations have been counted and we are delighted to announce that the shortlist for the 8th Annual ViE Awards has now been chosen. Join us at the World Vaccine Congress on April 7-9 to…
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis announced the Gynecologic Oncology Group (GOG) has commenced enrollment in Phase 2 study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the treatment of persistent or recurrent cervical cancer. In addition, the study now includes repeated cycles of treatment. Find out more: http://bit.ly/1EX8DjK
Phase 2 Study of Advaxis's ADXS-HPV for the Treatment of Persistent or Recurrent Cervical Cancer Now Includes Repeated Cycles of Treatment. PRINCETON, N.J., March 11, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Dan O'Connor will present at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 10 a.m. EST in Boston, MA. http://bit.ly/1FNVaJk
PRINCETON, N.J., March 2, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, will present at the Cowen and Company 35th Annual ...
1
Add a comment...
 
Find out why scientists are saying, "Cancer immunotherapy is the most exciting thing we have going on in the field" in NPR's podcast series "Living Cancer." http://n.pr/1yiQ3eB
Our immune systems constantly fight off disease — protecting us from colds, flu and infection. An experimental treatment called immunotherapy is helping patients' immune systems fight off cancer.
1
Add a comment...
People
Have them in circles
26 people
yolande lorijn's profile photo
Christina Kindborg's profile photo
David Miller's profile photo
Katherine Johnston's profile photo
Liz Peters's profile photo
Vincent Grillo's profile photo
jim dooley's profile photo
Eduardo Zawadzki's profile photo
Corsilo Japon's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.